Sutro Biopharma (STRO) Investor Presentation - Slideshow

STRO-002 Clinical Trial Updates - Interim data from the dose expansion cohort of the STRO-002 Phase 1 study in advanced ovarian cancer showed a 333% objective response rate (ORR) in all 33 evaluable patients, unenriched for FolRα expression[52] - A higher response rate of 471% ORR was observed in patients starting at the 52 mg/kg dose level of STRO-002[52] - Exploratory analysis suggests that a Tumor Proportion Score (TPS) > 25% correlated with a higher response rate, demonstrating a 400% ORR (10/25) in patients at the 52 mg/kg starting dose[68, 76] - The company plans to initiate a pivotal trial in ovarian cancer by year-end 2022[13] - First patient dosed in endometrial cancer cohort in November 2021[13] - First patient dosed in bevacizumab combination trial in Q1 2022[13] STRO-001 Clinical Trial Updates - STRO-001 is undergoing Phase 1 dose escalation study with NHL update at ASH 2020[88] - As of October 2021, the last reported doses levels were of 50 mg/kg in the multiple myeloma (MM) cohort and 42 mg/kg in the non-Hodgkin's lymphoma (NHL) cohort[91] Financial Status - The company reported $2542 million in cash, cash equivalents, and marketable securities as of September 30, 2021[99] - Projected cash runway into 2H 2023, based on current business plans and assumptions[99] - Funding received from collaborators of approximately $434 million through September 30, 2021[99]